On May 8, 2017, The European Commission has granted marketing authorization for “Dinutuximab beta Apeiron”, an antibody-based immunotherapy the rare pediatric cancer neuroblastoma. Thanks to the Vienna-based Biotech company Apeiron Biologics AG (“Apeiron”) patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of management and employees, academic institutions, Austrian private investors, business angels as well as public and private research initiatives.